Inducible In Vivo Silencing of Brd4 Identifies Potential Toxicities of Sustained BET Protein Inhibition

Abstract

BET family proteins are novel therapeutic targets for cancer and inflammation and represent the first chromatin readers against which small-molecule inhibitors have been developed. First-generation BET inhibitors have shown therapeutic efficacy in preclinical models, but the consequences of sustained BET protein inhibition in normal tissues remain poorly characterized. Using an inducible and reversible transgenic RNAi mouse model, we show that strong suppression of the BET protein Brd4 in adult animals has dramatic effects in multiple tissues. Brd4-depleted mice display reversible epidermal hyperplasia, alopecia, and decreased cellular diversity and stem cell depletion in the small intestine. Furthermore, Brd4-suppressed intestines are sensitive to organ stress and show impaired regeneration following irradiation, suggesting that concurrent Brd4 suppression and certain cytotoxic therapies may induce undesirable synergistic effects. These findings provide important insight into Brd4 function in normal tissues and, importantly, predict several potential outcomes associated with potent and sustained BET protein inhibition.

References 28

1. 1.

   Belkina AC, Denis GV. BET domain co-regulators in obesity, inflammation and cancer. Nat. Rev. Cancer. 2012;12:465-477.

   Not in our library10.1038/nrc3256

2. 2.

   Dekaney CM, Gulati AS, Garrison AP, Helmrath MA, Henning SJ. Regeneration of intestinal stem/progenitor cells following doxorubicin treatment of mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2009;297:G461-G470.

   Not in our library10.1152/ajpgi.90446.2008

3. 3.

   Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146:904-917.

   Not in our library10.1016/j.cell.2011.08.017

4. 4.

   Dey A, Nishiyama A, Karpova T, McNally J, Ozato K. Brd4 marks select genes on mitotic chromatin and directs postmitotic transcription. Mol. Biol. Cell. 2009;20:4899-4909.

   Not in our library10.1091/mbc.e09-05-0380

5. 5.

   Dow LE, Premsrirut PK, Zuber J, Fellmann C, McJunkin K, Miething C, Park Y, Dickins RA, Hannon GJ, Lowe SW. A pipeline for the generation of shRNA transgenic mice. Nat. Protoc. 2012;7:374-393.

   Not in our library10.1038/nprot.2011.446

6. 6.

   Durand A, Donahue B, Peignon G, Letourneur F, Cagnard N, Slomianny C, Perret C, Shroyer NF, Romagnolo B. Functional intestinal stem cells after Paneth cell ablation induced by the loss of transcription factor Math1 (Atoh1). Proc. Natl. Acad. Sci. USA. 2012;109:8965-8970.

   Not in our library10.1073/pnas.1201652109

7. 7.

   Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, et al. Selective inhibition of BET bromodomains. Nature. 2010;468:1067-1073.

   Not in our library10.1038/nature09504

8. 8.

   Floyd SR, Pacold ME, Huang Q, Clarke SM, Lam FC, Cannell IG, Bryson BD, Rameseder J, Lee MJ, Blake EJ, et al. The bromodomain protein Brd4 insulates chromatin from DNA damage signalling. Nature. 2013;498:246-250.

   Not in our library10.1038/nature12147

9. 9.

   French CA, Miyoshi I, Aster JC, Kubonishi I, Kroll TG, Dal Cin P, Vargas SO, Perez-Atayde AR, Fletcher JA. BRD4 bromodomain gene rearrangement in aggressive carcinoma with translocation t(15;19). Am. J. Pathol. 2001;159:1987-1992.

   Not in our library10.1016/s0002-9440(10)63049-0

10. 10.

    Grayson AR, Walsh EM, Cameron MJ, Godec J, Ashworth T, Ambrose JM, Aserlind AB, Wang H, Evan GI, Kluk MJ, et al. MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma. Oncogene. 2014;33:1736-1742.

    Not in our library10.1038/onc.2013.126

11. 11.

    Gregorieff A, Pinto D, Begthel H, Destrée O, Kielman M, Clevers H. Expression pattern of Wnt signaling components in the adult intestine. Gastroenterology. 2005;129:626-638.

    Not in our library10.1016/j.gastro.2005.06.007

12. 12.

    Houzelstein D, Bullock SL, Lynch DE, Grigorieva EF, Wilson VA, Beddington RS. Growth and early postimplantation defects in mice deficient for the bromodomain-containing protein Brd4. Mol. Cell. Biol. 2002;22:3794-3802.

    Not in our library10.1128/mcb.22.11.3794-3802.2002

13. 13.

    Huang B, Yang XD, Zhou MM, Ozato K, Chen LF. Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA. Mol. Cell. Biol. 2009;29:1375-1387.

    Not in our library10.1128/mcb.01365-08

14. 14.

    Lockwood WW, Zejnullahu K, Bradner JE, Varmus H. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc. Natl. Acad. Sci. USA. 2012;109:19408-19413.

    Not in our library10.1073/pnas.1216363109

15. 15.
    Small-Molecule Inhibition of BRDT for Male Contraception · 2012

    No notice
16. 16.

    McJunkin K, Mazurek A, Premsrirut PK, Zuber J, Dow LE, Simon J, Stillman B, Lowe SW. Reversible suppression of an essential gene in adult mice using transgenic RNA interference. Proc. Natl. Acad. Sci. USA. 2011;108:7113-7118.

    Not in our library10.1073/pnas.1104097108

17. 17.

    Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA, Bergeron L, Sims RJ. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl. Acad. Sci. USA. 2011;108:16669-16674.

    Not in our library10.1073/pnas.1108190108

18. 18.

    Metcalfe C, Kljavin NM, Ybarra R, de Sauvage FJ. Lgr5+ stem cells are indispensable for radiation-induced intestinal regeneration. Cell Stem Cell. 2014;14:149-159.

    Not in our library10.1016/j.stem.2013.11.008

19. 19.

    Mirguet O, Gosmini R, Toum J, Clément CA, Barnathan M, Brusq JM, Mordaunt JE, Grimes RM, Crowe M, Pineau O, et al. Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains. J. Med. Chem. 2013;56:7501-7515.

    Not in our library10.1021/jm401088k

20. 20.

    Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, Chung CW, Chandwani R, Marazzi I, Wilson P, Coste H, et al. Suppression of inflammation by a synthetic histone mimic. Nature. 2010;468:1119-1123.

    Not in our library10.1038/nature09589

21. 21.

    Premsrirut PK, Dow LE, Kim SY, Camiolo M, Malone CD, Miething C, Scuoppo C, Zuber J, Dickins RA, Kogan SC, et al. A rapid and scalable system for studying gene function in mice using conditional RNA interference. Cell. 2011;145:145-158.

    Not in our library10.1016/j.cell.2011.03.012

22. 22.

    Premsrirut PK, Dow LE, Park Y, Hannon GJ, Lowe SW. Creating transgenic shRNA mice by recombinase-mediated cassette exchange. Cold Spring Harb Protoc. 2013;2013:835-842.

    Not in our library10.1101/pdb.prot077057

23. 23.

    Sato T, van Es JH, Snippert HJ, Stange DE, Vries RG, van den Born M, Barker N, Shroyer NF, van de Wetering M, Clevers H. Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. Nature. 2011;469:415-418.

    Not in our library10.1038/nature09637

24. 24.

    Wang R, Li Q, Helfer CM, Jiao J, You J. Bromodomain protein Brd4 associated with acetylated chromatin is important for maintenance of higher-order chromatin structure. J. Biol. Chem. 2012;287:10738-10752.

    Not in our library10.1074/jbc.m111.323493

25. 25.

    Wu SY, Chiang CM. The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation. J. Biol. Chem. 2007;282:13141-13145.

    Not in our library10.1074/jbc.r700001200

26. 26.

    Yang Z, He N, Zhou Q. Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression. Mol. Cell. Biol. 2008;28:967-976.

    Not in our library10.1128/mcb.01020-07

27. 27.

    Zuber J, Rappaport AR, Luo W, Wang E, Chen C, Vaseva AV, Shi J, Weissmueller S, Fellmann C, Taylor MJ, et al. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev. 2011a;25:1628-1640.

    Not in our library10.1101/gad.17269211

28. 28.

    Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011b;478:524-528.

    Not in our library10.1038/nature10334

Cited by papers we hold 7

• Bromodomain and extraterminal (BET) proteins: biological functions, diseases and targeted therapy · 2023
  No notice
• Current strategies for the design of PROTAC linkers: a critical review · 2020
  No notice
• Bromodomain and Extra-Terminal Motif Inhibitors: a Review of Preclinical and Clinical Advances in Cancer Therapy · 2019
  No notice
• Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles · 2018
  No notice
• Epigenetics and Cancer Stem Cells: Unleashing, Hijacking, and Restricting Cellular Plasticity · 2017
  No notice
• Brd4 binds to active enhancers to control cell identity gene induction in adipogenesis and myogenesis · 2017
  No notice
• Bromodomain Protein BRD4 Is a Transcriptional Repressor of Autophagy and Lysosomal Function · 2017
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.